Drugmakers will have to notify the FDA about interruptions or discontinuances in the manufacturing of life-saving treatments under a proposed rule, which the agency is set to publish. The rule would mandate early notification from makers of drugs considered life-sustaining, life-supporting or used in the treatment or prevention of debilitating diseases.

Related Summaries